在硬皮病相关肺动脉高压中，使用安立生坦和他达拉非初始治疗改善右心室应变 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.在硬皮病相关肺动脉高压中，使用安立生坦和他达拉非初始治疗改善右心室应变

Am J Respir Crit Care Med. 2018 Feb 1;197(3):388-391. doi: 10.1164/rccm.201704-0789LE.

2

Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.使用安立生坦和他达拉非联合疗法治疗新诊断的结节病相关肺动脉高压。

Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):234-238. doi: 10.36141/svdld.v37i2.9343. Epub 2020 Jun 30.

3

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.安立生坦和他达拉非初始联合治疗硬皮病相关肺动脉高压

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102-10. doi: 10.1164/rccm.201507-1398OC.

4

Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).初始他达拉非和安贝生坦联合治疗肺动脉高压：临床和血液动力学长期疗效（ITALY 研究）。

J Cardiovasc Med (Hagerstown). 2018 Jan;19(1):12-17. doi: 10.2459/JCM.0000000000000590.

5

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.安立生坦与他达拉非初始联合治疗结缔组织病相关肺动脉高压（CTD-PAH）：来自AMBITION试验的亚组分析

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

6

Ambrisentan (Letairis) and tadalafil (Adcirca) for pulmonary arterial hypertension.

Med Lett Drugs Ther. 2016 Jan 4;58(1485):2-4.

7

Ambrisentan: a review of its use in pulmonary arterial hypertension.安贝生坦：用于肺动脉高压的评价。

Ther Adv Respir Dis. 2017 Jun;11(6):233-244. doi: 10.1177/1753465817696040. Epub 2017 Apr 20.

8

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.初始使用安贝生坦联合他达拉非治疗肺动脉高压。

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

9

Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!结缔组织病中肺动脉高压的筛查与早期检测。是时候开展这项工作了！

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1032-3. doi: 10.1164/rccm.201509-1881ED.

10

Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.肺动脉高压的 upfront 三联疗法可降低风险和逆转右心重构。

Chest. 2020 Feb;157(2):376-383. doi: 10.1016/j.chest.2019.09.009. Epub 2019 Sep 26.

引用本文的文献

1

Myocardial Disease in Systemic Sclerosis: Recent Updates and Clinical Implications.系统性硬化症中的心肌病：最新进展与临床意义

Curr Cardiol Rep. 2025 Jan 4;27(1):3. doi: 10.1007/s11886-024-02164-w.

2

Defining Echocardiographic Degrees of Right Heart Size and Function in Pulmonary Vascular Disease from the PVDOMICS Study.从PVDOMICS研究中定义肺血管疾病中右心大小和功能的超声心动图分级

Circ Cardiovasc Imaging. 2024 Oct;17(10). doi: 10.1161/circimaging.124.017074. Epub 2024 Oct 15.

3

Risk stratification and treatment goals in pulmonary arterial hypertension.肺动脉高压的风险分层和治疗目标。

Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01323-2024. Print 2024 Oct.

4

Sildenafil Versus Placebo for Early Pulmonary Vascular Disease in Scleroderma (SEPVADIS): protocol for a randomized controlled trial.硬皮病肺血管早期病变（SEPVADIS）患者应用西地那非与安慰剂的随机对照试验研究方案

BMC Pulm Med. 2024 Apr 30;24(1):211. doi: 10.1186/s12890-024-02892-3.

5

Beyond the Beaten Path of Right Ventricular Assessment: Using Right Ventricular Fractional Shortening in Patients With Heart Transplants.右心室评估的新途径：心脏移植患者右心室短轴缩短率的应用

J Am Heart Assoc. 2024 Mar 19;13(6):e033989. doi: 10.1161/JAHA.124.033989. Epub 2024 Mar 8.

6

Cardiac magnetic resonance assessment of cardiac involvement in autoimmune diseases.自身免疫性疾病心脏受累的心脏磁共振评估

Front Cardiovasc Med. 2023 Sep 22;10:1215907. doi: 10.3389/fcvm.2023.1215907. eCollection 2023.

7

Defining minimal detectable difference in echocardiographic measures of right ventricular function in systemic sclerosis.超声心动图测量系统性硬化症右心功能指标的最小可检测差异。

Arthritis Res Ther. 2022 Jun 18;24(1):146. doi: 10.1186/s13075-022-02835-5.

8

Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart.新型肺动脉及右心影像学方法

Circ Res. 2022 Apr 29;130(9):1445-1465. doi: 10.1161/CIRCRESAHA.121.319990. Epub 2022 Apr 28.

9

Cardiovascular Imaging for Systemic Sclerosis Monitoring and Management.用于系统性硬化症监测与管理的心血管成像

Front Cardiovasc Med. 2022 Mar 31;9:846213. doi: 10.3389/fcvm.2022.846213. eCollection 2022.

10

Endothelin-1 axes in the framework of predictive, preventive and personalised (3P) medicine.预测、预防和个性化（3P）医学框架下的内皮素-1轴

EPMA J. 2021 Aug 4;12(3):265-305. doi: 10.1007/s13167-021-00248-z. eCollection 2021 Sep.

本文引用的文献

1

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.安立生坦与他达拉非初始联合治疗结缔组织病相关肺动脉高压（CTD-PAH）：来自AMBITION试验的亚组分析

Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30.

2

Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients.系统性硬化症患者右心室纵向应变的独特异常

Circ Cardiovasc Imaging. 2016 Jun;9(6). doi: 10.1161/CIRCIMAGING.115.003792. Epub 2016 Jun 7.

3

Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.安立生坦和他达拉非初始联合治疗硬皮病相关肺动脉高压

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102-10. doi: 10.1164/rccm.201507-1398OC.

4

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.初始使用安贝生坦联合他达拉非治疗肺动脉高压。

N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687.

5

Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.特发性与结缔组织病相关肺动脉高压的治疗反应比较。

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1111-7. doi: 10.1164/rccm.201507-1456OC.

6

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.超声心动图成人左心室容量和射血分数测量：美国超声心动图学会和欧洲心血管影像协会的更新建议。

J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003.

7

Reference Values for Right Ventricular Strain in Patients without Cardiopulmonary Disease: A Prospective Evaluation and Meta-Analysis.无心肺疾病患者右心室应变的参考值：一项前瞻性评估与荟萃分析

Echocardiography. 2015 May;32(5):787-96. doi: 10.1111/echo.12806. Epub 2014 Oct 17.

8

Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.右心对肺动脉高压的适应：生理学和病理生物学。

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33. doi: 10.1016/j.jacc.2013.10.027.

9

Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.在现代，患有肺动脉高压的系统性硬化症患者的生存率并未得到改善。

Chest. 2013 Oct;144(4):1282-1290. doi: 10.1378/chest.12-0653.

10

Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.成人右心超声心动图评估指南：美国超声心动图学会报告，得到欧洲心脏病学会注册分支欧洲超声心动图协会以及加拿大超声心动图学会认可。

J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. doi: 10.1016/j.echo.2010.05.010.

Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.

作者信息

Mercurio Valentina, Mukherjee Monica, Tedford Ryan J, Zamanian Roham T, Khair Rubina M, Sato Takahiro, Minai Omar A, Torres Fernando, Girgis Reda E, Chin Kelly, Damico Rachel, Kolb Todd M, Mathai Stephen C, Hassoun Paul M

机构信息

1 Johns Hopkins University School of Medicine Baltimore, Maryland.

2 Stanford University Stanford, California.

出版信息

Am J Respir Crit Care Med. 2018 Feb 1;197(3):388-391. doi: 10.1164/rccm.201704-0789LE.

DOI:10.1164/rccm.201704-0789LE

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5803650/

Abstract

摘要